Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Weight Loss in Knee OA Patients Sustained With Liraglutide

Publish date:: July 29, 2019

Key clinical point: After an intensive weight-loss program to reduce knee osteoarthritis pain, liraglutide preserved weight loss relative to placebo.

Major finding: At 52 weeks, placebo-treated patients gained 1.17 kg, but those treated with liraglutide lost an additional 2.76 kg (P = .008)

Data source: A randomized, double-blind, placebo-controlled trial of 156 patients with knee OA.

Disclosures: Dr. Kristensen reported financial relationships with multiple pharmaceutical companies. The trial received funding from Novo Nordisk.

Citation:

Kristensen LE et al. Ann Rheum Dis. Jun 2019;78(Suppl 2):71-2. Abstract OP0011. doi: 10.1136/annrheumdis-2019-eular.1375.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Annual WCC visits significantly limit asthma worsening,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Microplastics permeate human placentas,

Must Reads in Rheumatology

Osteoporosis prevalence in PsA similar to general population,

Weight loss may be paramount lifestyle change in preventing gout,

Gut microbiome influences response to methotrexate in new-onset RA patients,

Oral steroids plus PPIs increase osteoporotic fracture risk in RA patients,

Etanercept may not help some with suspected nonradiographic axial spondyloarthritis,